Screener
Climb Bio, Inc. CLYM Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,768,543 and 47,766,338 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 5 |
| Additional paid-in capital | 451,372 | 449,762 |
| Accumulated other comprehensive income | 157 | 435 |
| Accumulated deficit | (303,449) | (289,727) |
| Total stockholders’ equity | 148,085 | 160,475 |
| Total liabilities and stockholders’ equity | $152,372 | $167,744 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s total equity?
- Climb Bio, Inc. (CLYM) reported total equity of $148.09M in Q1 2026.
- How has Climb Bio, Inc.'s total equity changed year-over-year?
- Climb Bio, Inc.'s total equity decreased by 23.4% year-over-year, from $193.39M to $148.09M.
- What is the long-term trend for Climb Bio, Inc.'s total equity?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s total equity has grown at a 45.1% compound annual growth rate (CAGR), from -$24.98M to $160.48M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Climb Bio, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude